个人简介
Dr Kim Lawson received his BTech (Hons) in pharmacology from Bradford University and a PhD in pharmacology from Sunderland University. He has an international reputation in Drug Discovery Research, gained in academia and multinational pharmaceutical industries (France: Rhone-Poulenc, Recherche Syntex France; Belgium: Sanofi-Labaz; UK: Reckitt & Colman, British Biotech) and now lectures at Sheffield Hallam University in pharmacology and physiology.
研究领域
Pharmacology of potassium channels
Modulation of K channel activity offers a therapeutic advantage by influencing the stability of cells and as a mechanism to rectify pathophysiological states. Specific modulators (openers and blockers) have been identified for a limited number K channel subtypes. The scope of this field is emerging and the number of likely therapeutic indications for K channel modulators will increase as insight into the dynamics of expression of these channels in various diseases grows and the issues of required selectivity are resolved.
Current research is designed to gain greater understanding of the role of K channels in cell regulation and their potential as therapeutic targets. Programs of work have an emphasis on the rational design and evaluation of agents acting on BKCa channels and KATP channels. In addition, interaction of drug entities with hERG channels are being investigated for the development of an in silico prediction model of drug safety.
Fibromyalgia
Fibromyalgia Syndrome (FM) is a chronic condition that presents with a complex of symptoms that include widespread pain, fatigue, dysfunctional sleep and cognitive disruption. FM is described as a condition of heightened generalized sensitization to sensory input, where the pathophysiology includes dysfunction of the CNS pain modulatory systems, dysfunction of the neuroendocrine system, and dysautonomia. Progress in the identification of effective treatments of FM has been made recently.
Current research is focused on the identification of drug targets to enable rational design of agents for the management of FM, exploration of improved methods of diagnosis and the investigation of the current management and awareness of FM.
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
KIRBY, R.W., MARTELLI, A., CALDERONE, V., McKAY, N.G. and LAWSON, Kim. (2013) Large conductance Ca2+-activated K+ channel (BKCa) activating properties of a series of novel N-arylbenzamides : channel subunit dependent effects Bioorg Med Chem. 21, 4186-4191.
LAWSON, Kim (2016). Potential drug therapies for the treatment of fibromyalgia. Expert opinion on investigational drugs, 1-11.
LAWSON, Kim (2014). Clinical trials for patients with fibromyalgia syndrome. Clinical & Experimental Pharmacology, 04 (05).
MARTELLI, A., TESTAI, L., BRESCHI, M.C., LAWSON, Kim, MCKAY, Neil, MICELI, F., TAGLIALATELA, M. and CALDERONE, V. (2013). Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacological Research, 70 (1), 27-34.
BEARD, S M, ROSKELL, N, LE, T K, ZHAO, Y, COLEMAN, A, ANG, D and LAWSON, Kim (2011). Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. Journal of medical economics.
VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2011). Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: effect of potassium channel modulators. European Journal of Pharmacology, 660 (2-3), 431-437.
VAHABI, B., MCKAY, N. G., LAWSON, K. and SELLERS, D. J. (2010). The role of c-kit-positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin-induced diabetic rats. BJU International.
PUTTINI, P. Sarzi, HÄUSER, W., LAWSON, Kim and SPROTT, H. (2009). 11 Topical Seminar Summary: FIBROMYALGIA SYNDROME. European Journal of Pain, 13, S5-S6.
VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2009). Cholinergic modulation of spontaneous activity in bladder strips from the diabetic rat : effect of the mucosa. European Eurology Supplements, 8 (4), p. 177.